▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Samsung Bioepis’ Imraldi, a biosimilar for Humira, has earned more than 60 percent of the market in Germany, solidifying its landing in the European market, industry data indicated on...
[THE INVESTOR] The Korea Exchange, the operator of the nation’s equity market, seeks to review this week the accounting misconduct of the country’s second-largest biotech company by market cap, whic...
[THE INVESTOR] Samsung BioLogics said on Dec. 5 it has signed a contract with Saint-Gobain for supply of single-use biopharmaceutical manufacturing equipment. Under the deal, the French firm will s...
[THE INVESTOR] Korean biotech firm Hugel said on Dec. 4 that its botulinum toxin Botulax has received marketing approval from Taiwan’s Ministry of Health and Welfare. Shares of Hugel rose 3.85 perc...
[THE INVESTOR ] Celltrion said on Dec. 2 that the European Medicines Agency has accepted its application for marketing authorization to a subcutaneous version of Remsima, its biosimilar of autoimmun...
[THE INVESTOR] Samsung BioLogics CEO Kim Tae-han reaffirmed key shareholders on Nov. 30 that the company’s accounting practice was legitimate, seeking a court injunction to nullify disciplinary acti...
[THE INVESTOR] Celltrion said on Nov. 29 it has obtained marketing authorization from the US Food and Drug Administration for Truxima, its copy version of Roche’s Rituxan (rituximab), to treat non-H...
[THE INVESTOR] Samsung BioLogics said on Nov. 28 it has filed an administrative lawsuit against a recent ruling by the country‘s financial regulator that the company violated accounting rules. T...
[THE INVESTOR] Korean display module firm Enerzent said on Nov. 22 it has signed an engineering, procurement and construction contract with US-based Micronoc for the design of energy consumption sol...
[THE INVESTOR] The growth of digital health care industry in Korea is being hindered by red tape in personal medical data and telemedicine sectors, a group of startups said on Nov. 22. The Asan Nan...
[THE INVESTOR] Celltrion refuted on Nov. 21 a news report that founder and Chairman Seo Jung-jin threw his weight around and abused a flight attendant last week. This follows a report by local cabl...
[THE INVESTOR] Korea’s iNtRon Biotechnology said on Nov. 20 it has clinched a deal with Switzerland-based Roivant Sciences to out-license SAL200, an investigational biologic for the treatment of inf...
[THE INVESTOR] Kolon Life Science said on Nov. 19 it has entered an agreement with Mundipharma to license out Invossa, its gene therapy designed to treat osteoarthritis, for the Japanese market, in ...
[THE INVESTOR] Korea’s leading biosimilar manufacturer Celltrion said on Nov. 19 that it has won approval from the US Food and Drug Administration for its tablet for treating HIV in the United State...
[THE INVESTOR] Bridge Biotherapeutics said on Nov. 19 it has filed an Investigational New Drug application with the US Food and Drug Administration to initiate phase 1 trials of BBT-877, a potent be...
IMM Investment, JKL Partners acquire GS ITM
Mirae Asset’s Indian unit boasts W4tr AUM
KT strengthens 5G partnership in Northern Europe
Berkeley Center’s Adam Sterling on future of VCs, startup ecosystem
Samsung’s new smartphone with Infinity O display hints at upcoming Galaxy S10
Former MP Group chairman quits management
Hana Alternative Asset to acquire Booyoung’s building in Seoul
Samsung to hold biannual conference for global execs
December 13, 2018
